MannKind Corporation (NASDAQ: MNKD) is a small company based in Valencia, California, poised to launch its FDA approved drug, Afrezza, as treatment indications for both Type 1 and Type 2 diabetes. Despite near unanimous backing from experts at the Advisory Committee (ADCOM) and the medical community, Mr. Market is still pessimistic on the company.  MannKind Corporation (NASDAQ:MNKD) stock performance was -2.50% in last session and finished the day at $8.77. Traded volume was 50.00million shares in the last session and the average volume of the stock remained 10.47million shares. The beta of the stock remained 1.24. MannKind Corporation (NASDAQ:MNKD) insider ownership is 0.50%.

Pfizer Inc’s vulnerability to cheaper generics and its weak roster of experimental medicines will be on display Tuesday when the company reports quarterly earnings, reviving interest in its pursuit of AstraZeneca Plc or other deals to fortify its pipeline. Pfizer Inc. (NYSE:PFE) dropped -0.49 percent to $30.19 Friday on volume of 14.4million shares. The intra-day range of the stock was $30.08 to $30.35. Pfizer Inc. (NYSE:PFE) has a market capitalization of $192.38billion.

AbbVie is developing an experimental triple-pill regimen for hepatitis C as a competitor to Gilead Sciences Inc.’s drug Sovaldi, which reaped $3.5bn in the second quarter.  Gilead Sciences, Inc. (NASDAQ:GILD)’s stock on July 25, 2014 reported a decrease of -0.77% to the closing price of $89.84. Its fifty two weeks range is $55.96 -$92.97. The total market capitalization recorded $137.10billion. The overall volume in the last trading session was 200.00million shares. In its share capital, GILD has 1.53billion outstanding shares.

Investors eyeing a purchase of ARIAD Pharmaceuticals ARIA -4.58%, Inc. (NASD: ARIA) stock, but cautious about paying the going market price of $5.88/share, might benefit from considering selling puts among the alternative strategies at their disposal. On Friday, shares of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) dropped -4.74% to close the day at $5.89. Company return on investment (ROI) is -93.20% and its monthly performance is recorded as -7.97%. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) quarterly revenue growth is -16.93%.

Bristol-Myers Squibb (NYSE:BMY)‘s stock had its “neutral” rating restated by Zacks in a report issued on Friday. They currently have a $52.00 target price on the stock. Zacks‘s price target indicates a potential upside of 5.28% from the company’s current price. Bristol-Myers Squibb Co (NYSE:BMY) stock performance was -0.14% in last session and finished the day at $49.39. Traded volume was 5.87million shares in the last session and the average volume of the stock remained 8.57million shares. The beta of the stock remained 0.48. Bristol-Myers Squibb Co (NYSE:BMY) insider ownership is 0.10%.